Common Genetic Variants Linked to Acute Myeloid Leukemia Risk and Survival

A meta-analysis identifies four new germline loci associated with specific cytogenetic subtypes and clinical outcomes in myeloid malignancy.

For Doctors in a Hurry

Clinicians lack a comprehensive understanding of the heritable genetic components that influence the risk of developing acute myeloid leukemia.
The researchers conducted a meta-analysis of six genome-wide association studies involving 4,710 cases of acute myeloid leukemia and 12,938 controls.
A new risk locus at 2p23.3 was identified with genome-wide significance, showing a p-value of 1.35 × 10-8 for disease risk.
The authors concluded that specific genetic variants contribute to the risk of developing distinct subgroups of acute myeloid leukemia.
These findings suggest that identifying subgroup-specific risk loci may eventually improve prognostic stratification and clinical management for patients with leukemia.

Mapping the Genetic Architecture of Myeloid Malignancy

Acute myeloid leukemia is defined by a complex landscape of somatic mutations that drive pathogenesis and dictate clinical outcomes [1]. Current diagnostic frameworks, such as the World Health Organization classification, increasingly rely on these molecular biomarkers to categorize disease and guide treatment selection [2, 3]. Despite these advances in understanding the somatic genome, the heritable component of leukemia risk outside of rare familial syndromes is not yet fully understood [4]. Clinicians currently utilize risk stratification models based on genetic aberrations to predict response to targeted therapies [5]. However, the interplay between a patient's germline background and the eventual development of specific cytogenetic subgroups remains a critical area of investigation. A new study now provides evidence linking common genetic variations to both overall risk and specific high-risk subtypes of the disease.

Meta-Analysis Identifies New Susceptibility Loci

To better define the genetic architecture of myeloid malignancy, the researchers performed a meta-analysis that integrated data from four previously published genome-wide association studies with two new datasets. A genome-wide association study (a large-scale genomic scan used to identify common genetic variations that occur more frequently in individuals with a specific disease than in healthy controls) provided the statistical power necessary to detect subtle genetic influences. This combined analysis included a total study population of 4,710 acute myeloid leukemia cases and 12,938 controls. While previous research has identified a small number of common genetic variants influencing risk, the heritable component of the disease outside of rare familial susceptibility syndromes remains largely undefined. This study addresses that gap by focusing on germline variants, which are the inherited DNA sequences present from birth that may predispose individuals to specific leukemia subtypes.

The researchers also investigated genetic loci previously associated with the risk of clonal hematopoiesis (the presence of genetically distinct subpopulations of blood cells in individuals without leukemia) or clonal hematopoiesis of indeterminate potential (a state where these subpopulations carry mutations linked to malignancy in the absence of cytopenia or overt disease). By examining these precursors, the authors identified several variants associated with the risk of acute myeloid leukemia, suggesting that inherited genetic factors may influence the early stages of leukemogenesis. This connection is vital for clinicians, as it suggests that the transition from age-related clonal expansion to overt malignancy may be partially governed by a patient's baseline genetic makeup. Understanding these inherited predispositions could eventually help physicians identify which patients with clonal hematopoiesis are at the highest risk for progression to acute leukemia.

A Prognostic Marker at the 2p23.3 Locus

The meta-analysis identified a new genome-wide significant risk locus for pan-acute myeloid leukemia at 2p23.3, a finding that applies across the broad spectrum of the disease rather than being limited to a single cytogenetic subtype. This locus is represented by the genetic variant rs4665765, which reached a high level of statistical significance with a P value of 1.35 × 10-8. Several genes are located within or near this 2p23.3 region, including EFR3B, POMC, DNMT3A, and DNAJC27. For the practicing clinician, the inclusion of DNMT3A is particularly notable, as somatic mutations in this gene are among the most frequent drivers of leukemogenesis and are already used in clinical practice to help risk-stratify patients at the time of diagnosis. The presence of a germline variant in the same gene suggests a multi-hit model where inherited and acquired mutations converge on the same biological pathways.

Beyond its role in disease susceptibility, the 2p23.3 locus also significantly associates with patient survival (P = 6.09 × 10-3). This finding suggests that inherited genetic factors do more than just increase the likelihood of developing a malignancy; they may also influence the underlying biology of the tumor or the host response to therapy, thereby affecting long-term clinical outcomes. While current prognostic models rely heavily on acquired mutations and cytogenetic abnormalities found in the leukemia cells themselves, the identification of a germline marker (an inherited genetic variation present in every cell of the patient's body) that correlates with survival provides a potential new tool for establishing a more precise prognosis. Understanding these inherited influences may eventually allow physicians to better identify patients who require more aggressive frontline interventions or closer monitoring for relapse based on their baseline genetic profile.

Genetic Predisposition to High-Risk Cytogenetic Subgroups

The meta-analysis further refined the genetic landscape of myeloid malignancy by identifying three new genome-wide significant risk loci for specific disease subgroups, suggesting that inherited factors influence not only the overall risk of leukemia but also the specific cytogenetic architecture of the resulting tumor. One such finding involves a risk locus for acute myeloid leukemia with deletions of chromosome 5 and/or 7 identified at 1q23.3. This locus, which is represented by the genetic variant rs12078864 (P = 7.0 × 10-10), is associated with the DUSP23 gene. For the clinician, this is particularly relevant because deletions of chromosome 5 or 7 are hallmark indicators of poor prognosis, often associated with resistance to standard chemotherapy and lower rates of complete remission. This discovery suggests that the development of these high-risk chromosomal deletions is not entirely stochastic but may be predisposed by specific germline variations.

The researchers also identified two distinct germline markers associated with cytogenetically complex acute myeloid leukemia, a high-risk category defined by the presence of multiple, concurrent chromosomal abnormalities. The first risk locus for cytogenetically complex acute myeloid leukemia was identified at 2q33.3, represented by the variant rs12988876 (P = 3.28 × 10-8) and associated with the PARD3B gene. A second risk locus for cytogenetically complex acute myeloid leukemia was identified at 2p21, where the variant rs79918355 (P = 1.60 × 10-9) is linked to the EPCAM gene. These findings indicate that certain patients may be biologically predisposed to developing more aggressive, genomically unstable forms of leukemia from the outset, potentially explaining why some individuals present with highly complex karyotypes that are traditionally difficult to manage with conventional intensive induction protocols.

Implications for Etiology and Risk Stratification

The identification of these genetic markers provides a clearer understanding of the etiology (the underlying causes and developmental pathways) of acute myeloid leukemia. By analyzing a large cohort of 4,710 cases and 12,938 controls, the researchers established that the genetic architecture of this malignancy is not uniform. Instead, the results demonstrate the existence of disease subgroup specific risk loci in acute myeloid leukemia, suggesting that inherited factors determine not only the likelihood of developing the disease but also the specific cytogenetic and molecular path the leukemia follows. For the clinician, this indicates that the biological heterogeneity observed at the time of diagnosis may be rooted in the patient's germline DNA, influencing whether they develop high-risk features such as complex karyotypes or specific chromosomal deletions.

A critical finding of this meta-analysis is the overlap between inherited risk and the early stages of leukemogenesis. The researchers investigated loci previously associated with the risk of clonal hematopoiesis or clonal hematopoiesis of indeterminate potential. They found that several variants associated with clonal hematopoiesis were also found to be associated with the risk of acute myeloid leukemia, suggesting a continuum of genetic risk where certain germline markers predispose individuals to both the initial clonal expansion and the subsequent progression to overt malignancy. This connection is exemplified by the pan-AML risk locus at 2p23.3 (rs4665765; P = 1.35 × 10-8), which involves the DNMT3A gene, a common site for somatic mutations in clonal hematopoiesis. These findings have significant implications for future risk stratification and clinical management. Because the 2p23.3 locus also significantly associates with patient survival (P = 6.09 × 10-3), these germline markers may eventually serve as prognostic tools alongside traditional somatic mutation testing. Identifying subgroup-specific risk loci, such as those for cytogenetically complex AML at 2q33.3 (rs12988876; P = 3.28 × 10-8) and 2p21 (rs79918355; P = 1.60 × 10-9), or deletions of chromosome 5 and/or 7 at 1q23.3 (rs12078864; P = 7.0 × 10-10), could allow for more precise screening of high-risk individuals and support future risk-adapted management strategies.

Study Info

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia

Diyanath Ranasinghe, Wei-Yu Lin, Sarah Fordham, Abrar Alharbi, et al.

Journal Blood

Published January 29, 2026